Related Experiment Video
Updated: May 6, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Xanomeline/trospium-induced polyuria: A patient case report
Henry Leach1, Francesca DiGuglielmo2
1Clinical Coordinator, PGY-2 Psychiatric Pharmacy Residency Program Director, Toms River New Jersey.
Xanomeline/trospium, a new schizophrenia treatment, can cause polyuria (frequent urination). This case report details a patient experiencing this side effect after dose increase, which resolved upon discontinuation.
Area of Science:
- Pharmacology
- Neuroscience
- Clinical Medicine
Background:
- Xanomeline/trospium is a novel agent for schizophrenia management, acting as an M1/M4 muscarinic acetylcholine receptor agonist with a peripheral muscarinic antagonist.
- Unlike traditional D2 receptor antagonists, its mechanism targets muscarinic pathways, potentially leading to unique side effect profiles.
- The coformulation with trospium aims to mitigate peripheral cholinergic effects, such as increased salivation and gastrointestinal issues.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Urinary Tract Calculi V: Nursing Management
Diabetes Insipidus I: Introduction
Diabetes Insipidus II: Pathophysiology
Type I Diabetes III: Clinical Manifestations

